Glycomine
2013
FOUNDED
PRIVATE
STATUS
Series A
LATEST DEAL TYPE
$12M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of nano medicines designed to develop a new generation of replacement therapies for rare diseases. The company's medicines include orphan drugs that combine replacement therapies - substrates, enzymes, or proteins - with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians treat their patients with for serious rare monogenic disorders of metabolism and protein misfolding.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Primary Office
- 953 Indiana Street
- San Francisco, CA 94107
- United States
+1 (415) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Glycomine’s full profile, request a free trial.
Glycomine Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 16-Nov-2016 | $12M | 0000 | 000.00 | Completed | Generating Revenue |
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Glycomine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Glycomine Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Avidity Biosciences | Venture Capital-Backed | La Jolla, CA | 00000 | 000000000000 | 00000 | |
| 00000000 000000000 | Venture Capital-Backed | Boston, MA | 000 | 00.000 | 0000000000 0 | 00.000 |
| 00000000 000000000 | Formerly VC-backed | Morrisville, NC | 00 | 00000 | 00000000 | 00000 |
| 0000 000000000000 | Corporate Backed or Acquired | London, United Kingdom | 00 | 00000000000 | ||
| 000000000 00000000 | Corporation | Pasadena, CA | 00 | 00.000 | 000000000 | 00.000 |
Glycomine Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Chiesi Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Pappas Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Sanderling Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| California Institute for Quantitative Biosciences | Accelerator/Incubator | 000 0000 | 000000 0 | |||
| JLABS | Accelerator/Incubator | 000 0000 | 000000 0 |
Glycomine Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Agnes Rafalko Ph.D | Founder, President, Board Member & Chief Executive Officer | ||
| Christopher Starr Ph.D | Executive Chairman | ||
| Patrice Rioux MD | Chief Medical Officer |